Is the use of narrow-spectrum antibiotics too narrow-minded in the treatment of severe infections

Clinical Microbiology and Infection

Volumn 6, Issue SUPPL. 2, 2000, Pages 7-10

  Hoffken G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antibiotic; Empirical therapy; Mortality; Pneumonia; Review; Severe infection

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; CROSS INFECTION; HUMAN; REVIEW;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; PNEUMONIA, BACTERIAL;

EID: 17644423532     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00003.x     Document Type: Article

References (16)

1. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153: 1711-25.
2. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998; 26: 2078-86.
3. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-8.
4. Verbist L. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. International Study Group. Scand J Infect Dis Suppl 1993; 91: 14-24.
5. Livermore DM. β-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41 (Suppl. D): 25-41.
6. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-24.
7. Rahal J. Extended-spectrum beta-lactamases: how big is the problem? Clin Microbiol Infect 2000; 6 (Suppl. 2): 2-6.
8. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997; 11: 813-49.
9. Péchère JC. Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. J Antimicrob Chemother 1999; 44 (Topic A): 11-18.
10. Carbon C. MRSA and MRSE: is there an answer? Clin Microbiol Infect 2000; 6 (Suppl. 2): 17-22.
11. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22: 387-94.
12. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113: 412-20.
13. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-85.
14. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990; 142: 369-73.
15. Thornsberry C, Yee YC. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J Med 1996; 24 (100): 26S-38S.
16. Mandell LA, Campbell GD Jr. Nosocomial pneumonia guidelines: an international perspective. Chest 1998; 113 (Suppl. 3): 188S-93S.